Jazz Pharmaceuticals JAZZ announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer (BTC). The drug will...
Puma Biotechnology, Inc. PBYI announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline candidate, alisertib, for the treatment of patients with metastatic breast cancer.The...
Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating cognitive impairment (CI) associated with Huntington’s Disease (HD) failed to...
Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion...
Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate FT819.Data showed...
Spero Therapeutics reports progress on tebipenem HBr trial; cash runway extended to mid-2026 amid restructuring.Quiver AI SummarySpero Therapeutics, Inc. announced its financial results for Q3 2024, reporting...